Globally, the diabetic nephropathy market is witnessing significant growth due to rise in the incidence of diabetes and obesity in different regions of the world. The global diabetic nephropathy market is likely to reach USD 3,145.9 million in 2020 (Persistence Market Research). At such rate, monitoring and management becomes crucial for diabetic patients. Recently, Proteomics International licensed their diabetic Kidney disease predictor test (PromarkerD) in the USA and Mexico. During his interaction with BSA, Dr Richard Lipscombe, CEO of Proteomics International talks about their star product, plans to launch in other countries and the future of diabetic kidney diagnosis.
